Zhou Yu
Rutgers, The State University of New Jersey
ORCID: 0000-0003-3213-4583Also affiliated with Agency for Science, Technology and Research, Brigham and Women's Hospital, Howard Hughes Medical Institute, Harvard University, Zhejiang University of Science and Technology, Janelia Research Campus, Washington University in St. Louis, Ningxia University, Stomatology Hospital, Xijing Hospital, Jining Medical University, Zhejiang University of Technology, Zhejiang University, Nanjing Medical University, Air Force Medical University
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 2 papers. Top paper: “Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775”.
Nicoletta Colombo, Antonio Casado, Alessandro D Santin, Emeline Colomba, David S. Miller +25 more
Damon T. Burrow, Jinmei Li, Jiwoong Park, Sandeep Kumar, Cheng Lyu +33 more